ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31

Zymeworks Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$25.54+0.51 (+2.04%)

Close on Oct 19, 2026

Market cap: $1.86B
P/E (TTM): –
Dividend yield: –

Zymeworks Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Stock-Based Compensation	28	18	8.10	4.02	11	29
Deferred Income Taxes	0.95	0.69	-0.76	1.94	-0.95	0.14
Change in Accounts Receivable	51	-36	14	-18	-0.27	-13
Change in Accounts Payable	-24	14	-45	26	16	7.62
Change in Unearned Revenue	-23	3.56	3.70	0	0	–
Operating Cash Flow	-33	-110	-118	144	-192	-151
Capital Expenditures	-1.52	-1.99	-2.47	-8.15	-12	-4.31
Purchase of Investments	-196	-284	-553	-113	-35	-51
Sale & Maturity of Investments	225	326	350	72	193	–
Investing Cash Flow	27	39	-207	-54	145	-43
Share Repurchases	-42	-30	0	0	–	–
Stock Issued	0	0	26	108	0	301
Financing Cash Flow	-19	-20	82	109	8.01	309
Foreign Exchange Rate Adjustments	-0.05	0.29	0.35	0.20	-0.33	-0.55
Net Change in Cash	-25	-91	-243	199	-40	114
Free Cash Flow	-35	-112	-121	136	-205	-156
Income Taxes Paid	1.35	3.18	0.17	10	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -419.0%
Net margin: -404.0%
Return on equity, FY2025: -26.7%

Financial strength

Current ratio: 6.32
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 379.8%

Valuation

P/E ratio: –
Price to sales: 50.21
Price to book: 23.20
Dividend yield: –